- Home
- ACHL
as 11-14-2024 1:30pm EST
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
| Founded: | 2016 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 40.4M | IPO Year: | 2021 |
| Target Price: | $2.83 | AVG Volume (30 days): | 126.9K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $1.76 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Achilles Therapeutics plc News
ACHL Breaking Stock News: Dive into ACHL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
Zacks
2 months ago
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
MT Newswires
2 months ago
Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment
GlobeNewswire
2 months ago
Achilles Therapeutics Announces Strategic Update
Simply Wall St.
3 months ago
Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?
GlobeNewswire
3 months ago
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
PR Newswire
5 months ago
Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than
PR Newswire
5 months ago
3 Major Product Releases at 3Shape Discover Event
Compare ACHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACHL Achilles Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.